Medicis Pharmaceutical Corporation 

(Public, NYSE:MRX)   Watch this stock   
Find more results for MRX
Dec 1, 2009
Piper Jaffray Healthcare Conference - 9:00AM EST - Add to calendar
Nov 11, 2009
Credit Suisse Healthcare Conference
Nov 4, 2009
Q3 2009 Earnings Conference Call - Webcast
Nov 4, 2009
Q3 2009 Earnings Release
Sep 22, 2009
UBS Global Life Sciences Conference
Sep 15, 2009
Morgan Stanley Global Healthcare Conference - Webcast
Sep 10, 2009
Thomas Weisel Partners Healthcare Conference
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 13.93% 1.98%
Operating margin 20.96% 7.95%
EBITD margin - 13.30%
Return on average assets 7.84% 0.94%
Return on average equity 12.87% 1.73%
Employees 611 -

Address

7720 North Dobson Road
Scottsdale, AZ 85256
United States - Map
+1-602-8088800 (Phone)
+1-602-8080822 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Medicis Pharmaceutical Corporation discussed on blogs

Medicis Pharmaceutical Corporation discussions

  View all discussions »

Description

Medicis Pharmaceutical Corporation (Medicis) is an independent specialty pharmaceutical company focused primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing in the United States of products for the treatment of dermatological, aesthetic and podiatric conditions. It also markets products in Canada for the treatment of dermatological and aesthetic conditions. It offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, skin and skin-structure infections, seborrheic dermatitis and cosmesis. It offers 18 branded products, including PERLANE (hyaluronic acid), RESTYLANE (hyaluronic acid), SOLODYN (minocycline HCl, USP), TRIAZ (benzoyl peroxide), VANOS (fluocinonide) Cream 0.1%, and ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel. On July 1, 2008, the Company acquired LipoSonix, Inc.

Officers and directors

Jonah Shacknai
Chairman of the Board, Chief Executive Officer
Age: 52
Bio & Compensation - Reuters
Richard D. Peterson
Chief Financial Officer, Executive Vice President, Treasurer
Age: 41
Bio & Compensation - Reuters
Mark A. Prygocki Sr.
Chief Operating Officer, Executive Vice President
Age: 42
Bio & Compensation - Reuters
Mitchell S. Wortzman Ph.D.
Executive Vice President, Chief Scientific Officer
Age: 58
Bio & Compensation - Reuters
Jason D. Hanson
Executive Vice President, General Counsel, Secretary
Age: 40
Bio & Compensation - Reuters
Vincent P. Ippolito
Executive Vice President - Sales and Marketing
Age: 50
Bio & Compensation - Reuters
Joseph P. Cooper
Executive Vice President - Corporate and Product Development
Age: 51
Bio & Compensation - Reuters
Arthur G. Altschul Jr.
Director
Age: 44
Bio & Compensation - Reuters
Michael A. Pietrangelo
Director
Age: 66
Bio & Compensation - Reuters
Philip S. Schein M.D.
Director
Age: 69
Bio & Compensation - Reuters